SDS Biotech K.K. Reports Consolidated Earnings Results for the Third Quarter Ended December 31, 2016; Revised Consolidated Earnings Guidance for the Full Year Ending March 31, 2017; Provides Dividend Guidance for the Full Year Ending March 31, 2017
The company revised consolidated earnings guidance for the full year ending March 31, 2017. For the year, the company expects to report net sales of JPY 14,820 million, operating income of JPY 670 million, ordinary income of JPY 610 million, net income of JPY 540 million or JPY 68.95 per share compared to net sales of JPY 16,210 million, operating income of JPY 1,460 million, ordinary income of JPY 1,220 million, net income of JPY 820 million or JPY 104.71 per share as previously expected.
The company also provided dividend guidance for the full year ending March 31, 2017. For the year, the company expects year-end dividend of JPY 12.50 per share compared to JPY 15.00 per share paid dividend a year ago.